173 related articles for article (PubMed ID: 37586773)
1. Immune dysfunction revealed by digital spatial profiling of immuno-oncology markers in progressive stages of renal cell carcinoma and in brain metastases.
Schoenfeld DA; Moutafi M; Martinez S; Djureinovic D; Merkin RD; Adeniran A; Braun DA; Signoretti S; Choueiri TK; Parisi F; Hurwitz M; Rimm DL; Wei W; Jilaveanu L; Kluger HM
J Immunother Cancer; 2023 Aug; 11(8):. PubMed ID: 37586773
[TBL] [Abstract][Full Text] [Related]
2. Tumor mutational burden and immune infiltrates in renal cell carcinoma and matched brain metastases.
Steindl A; Alpar D; Heller G; Mair MJ; Gatterbauer B; Dieckmann K; Widhalm G; Hainfellner JA; Schmidinger M; Bock C; Müllauer L; Preusser M; Berghoff AS
ESMO Open; 2021 Apr; 6(2):100057. PubMed ID: 33588158
[TBL] [Abstract][Full Text] [Related]
3. Spatial heterogeneity of tumor microenvironment influences the prognosis of clear cell renal cell carcinoma.
Zhang D; Ni Y; Wang Y; Feng J; Zhuang N; Li J; Liu L; Shen W; Zheng J; Zheng W; Qian C; Shan J; Zhou Z
J Transl Med; 2023 Jul; 21(1):489. PubMed ID: 37474942
[TBL] [Abstract][Full Text] [Related]
4. Comprehensive analyses of immune tumor microenvironment in papillary renal cell carcinoma.
de Vries-Brilland M; Rioux-Leclercq N; Meylan M; Dauvé J; Passot C; Spirina-Menand E; Flippot R; Fromont G; Gravis G; Geoffrois L; Chevreau C; Rolland F; Blanc E; Lefort F; Ravaud A; Gross-Goupil M; Escudier B; Negrier S; Albiges L
J Immunother Cancer; 2023 Nov; 11(11):. PubMed ID: 37935564
[TBL] [Abstract][Full Text] [Related]
5. Differential expression of TIM-3 between primary and metastatic sites in renal cell carcinoma.
Zhang X; Yin X; Zhang H; Sun G; Yang Y; Chen J; Shu K; Zhao J; Zhao P; Chen N; Wang J; Shen P; Zeng H
BMC Cancer; 2019 Jan; 19(1):49. PubMed ID: 30630458
[TBL] [Abstract][Full Text] [Related]
6. Characteristics and clinical impacts of the immune environments in colorectal and renal cell carcinoma lung metastases: influence of tumor origin.
Remark R; Alifano M; Cremer I; Lupo A; Dieu-Nosjean MC; Riquet M; Crozet L; Ouakrim H; Goc J; Cazes A; Fléjou JF; Gibault L; Verkarre V; Régnard JF; Pagès ON; Oudard S; Mlecnik B; Sautès-Fridman C; Fridman WH; Damotte D
Clin Cancer Res; 2013 Aug; 19(15):4079-91. PubMed ID: 23785047
[TBL] [Abstract][Full Text] [Related]
7. Multidiscipline Immunotherapy-Based Rational Combinations for Robust and Durable Efficacy in Brain Metastases from Renal Cell Carcinoma.
Lee HW
Int J Mol Sci; 2021 Jun; 22(12):. PubMed ID: 34208157
[TBL] [Abstract][Full Text] [Related]
8. Identification and validation of novel prognostic markers in Renal Cell Carcinoma.
Rabjerg M
Dan Med J; 2017 Oct; 64(10):. PubMed ID: 28975890
[TBL] [Abstract][Full Text] [Related]
9. Future perspectives in melanoma research : Meeting report from the "Melanoma Bridge". Napoli, December 1st-4th 2015.
Ascierto PA; Agarwala S; Botti G; Cesano A; Ciliberto G; Davies MA; Demaria S; Dummer R; Eggermont AM; Ferrone S; Fu YX; Gajewski TF; Garbe C; Huber V; Khleif S; Krauthammer M; Lo RS; Masucci G; Palmieri G; Postow M; Puzanov I; Silk A; Spranger S; Stroncek DF; Tarhini A; Taube JM; Testori A; Wang E; Wargo JA; Yee C; Zarour H; Zitvogel L; Fox BA; Mozzillo N; Marincola FM; Thurin M
J Transl Med; 2016 Nov; 14(1):313. PubMed ID: 27846884
[TBL] [Abstract][Full Text] [Related]
10. Characterization of papillary and clear cell renal cell carcinoma through imaging mass cytometry reveals distinct immunologic profiles.
Govindarajan A; Salgia NJ; Li H; Castro DV; Mirzapoiazova T; Armstrong B; Zhao D; Mercier BD; Dizman N; Chawla N; Zengin Z; Meza L; Tripathi N; Sayegh N; Chehrazi-Raffle A; Tripathi A; Pal SK
Front Immunol; 2023; 14():1182581. PubMed ID: 37638025
[TBL] [Abstract][Full Text] [Related]
11. Single-cell transcriptomics reveals a low CD8
Peng YL; Xiong LB; Zhou ZH; Ning K; Li Z; Wu ZS; Deng MH; Wei WS; Wang N; Zou XP; He ZS; Huang JW; Luo JH; Liu JY; Jia N; Cao Y; Han H; Guo SJ; Dong P; Yu CP; Zhou FJ; Zhang ZL
J Immunother Cancer; 2022 Feb; 10(2):. PubMed ID: 35121646
[TBL] [Abstract][Full Text] [Related]
12. Unveiling the tumor immune microenvironment of organ-specific melanoma metastatic sites.
Conway JW; Rawson RV; Lo S; Ahmed T; Vergara IA; Gide TN; Attrill GH; Carlino MS; Saw RPM; Thompson JF; Spillane AJ; Shannon KF; Shivalingam B; Menzies AM; Wilmott JS; Long GV; Scolyer RA; Pires da Silva I
J Immunother Cancer; 2022 Sep; 10(9):. PubMed ID: 36096531
[TBL] [Abstract][Full Text] [Related]
13. The prospect of targeting T cell immunoglobulin and mucin-domain containing-3 in renal cell carcinoma immunotherapy.
Mohsenzadegan M; Nowroozi MR; Fotovvat A; Bavandpour Baghshahi P; Bokaie S; Inanloo SH; Sharifi L
Scand J Immunol; 2022 Sep; 96(3):e13197. PubMed ID: 35700044
[TBL] [Abstract][Full Text] [Related]
14. Renal Cell Carcinoma-Infiltrating CD3
Lee HW; Park C; Joung JG; Kang M; Chung YS; Oh WJ; Yeom SY; Park WY; Kim TJ; Seo SI
Curr Issues Mol Biol; 2021 May; 43(1):226-239. PubMed ID: 34071865
[TBL] [Abstract][Full Text] [Related]
15. Transcriptomic signatures related to the obesity paradox in patients with clear cell renal cell carcinoma: a cohort study.
Sanchez A; Furberg H; Kuo F; Vuong L; Ged Y; Patil S; Ostrovnaya I; Petruzella S; Reising A; Patel P; Mano R; Coleman J; Russo P; Liu CH; Dannenberg AJ; Chan TA; Motzer R; Voss MH; Hakimi AA
Lancet Oncol; 2020 Feb; 21(2):283-293. PubMed ID: 31870811
[TBL] [Abstract][Full Text] [Related]
16. Evaluation of tumor microenvironment and biomarkers of immune checkpoint inhibitor response in metastatic renal cell carcinoma.
Brown LC; Zhu J; Desai K; Kinsey E; Kao C; Lee YH; Pabla S; Labriola MK; Tran J; Dragnev KH; Tafe LJ; Dayyani F; Gupta RT; McCall S; George DJ; Glenn ST; Nesline MK; George S; Zibelman M; Morrison C; Ornstein MC; Zhang T
J Immunother Cancer; 2022 Oct; 10(10):. PubMed ID: 36252996
[TBL] [Abstract][Full Text] [Related]
17. [Immunotherapy Based on Tumor Microenvironment in Renal Cell Carcinoma].
Han SC; Yin HQ; Xu T
Zhongguo Yi Xue Ke Xue Yuan Xue Bao; 2022 Apr; 44(2):305-312. PubMed ID: 35538767
[TBL] [Abstract][Full Text] [Related]
18. Spatial and temporal heterogeneity of tumor immune microenvironment between primary tumor and brain metastases in NSCLC.
Liu JS; Cai YX; He YZ; Xu J; Tian SF; Li ZQ
BMC Cancer; 2024 Jan; 24(1):123. PubMed ID: 38267913
[TBL] [Abstract][Full Text] [Related]
19. The tumor immune microenvironment of primary and metastatic HER2- positive breast cancers utilizing gene expression and spatial proteomic profiling.
Schlam I; Church SE; Hether TD; Chaldekas K; Hudson BM; White AM; Maisonet E; Harris BT; Swain SM
J Transl Med; 2021 Nov; 19(1):480. PubMed ID: 34838031
[TBL] [Abstract][Full Text] [Related]
20. Single-Cell Profiling Comparisons of Tumor Microenvironment between Primary Advanced Lung Adenocarcinomas and Brain Metastases and Machine Learning Algorithms in Predicting Immunotherapeutic Responses.
Wu Y; Kang K; Han C; Wang L; Wang Z; Zhao A
Biomolecules; 2023 Jan; 13(1):. PubMed ID: 36671569
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]